Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 3/20 | 0.55 |
| ▸ | HTR1B | P28222 | 3/20 | 0.55 |
| ▸ | HTR1F | P30939 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3623303 | 0.92 | HTR6 (0.50) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3624451 | 0.87 | HTR6 (0.52) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL1996280 | 0.84 | HTR6 (0.63) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3619807 | 0.83 | HTR6 (0.62) | HTR6DRD3DRD2HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL3623637 | 0.82 | HTR6 (0.60) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3620380 | 0.82 | HTR6 (0.49) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3617642 | 0.82 | HTR6 (0.54) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3622623 | 0.81 | HTR6 (0.52) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3623305 | 0.78 | HTR6 (0.46) | HTR6DRD3DRD2HTR1AHTR1D | |
| SCHEMBL3622409 | 0.78 | HTR6 (0.77) | HTR6DRD3DRD2HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | claimed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | claimed |
| CN-101484420-A | Indoles as 5-HT 6 modulators | BIOVITRUM AB PUBL (SE) | 2009-07-15 | — | — | CN | claimed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | claimed |
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| CN-101484420-A | Indoles as 5-HT 6 modulators | BIOVITRUM AB PUBL (SE) | 2009-07-15 | — | — | CN | disclosed |
| EP-2046741-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (publ) (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2008003703-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885DRD3 77/4885DRD2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.